Our Mission
Quantum Pharma’s mission is primarily to support an improvement in the quality of life of patients through supply of diagnostic and therapeutic radiopharmaceuticals, and involvement in early-stage research and development of new diagnostic and therapeutic options for improved clinical outcomes.
Work with us!Quantum Pharma's Story
Quantum Pharma's story started in 2015 when radiopharmacists Brett Greer and Peter Eu commenced a radiopharmacy service in Melbourne, Australia, to make available for clinical use radiopharmaceuticals in the then novel field of theranostics. As demand for these services grew over the next few years Brett and Peter ventured into providing radiopharmacy services for clinical radiopharmaceutical trials in collaboration with multinational pharmaceutical companies and Australian clinical sites. This expansion naturally led into providing early phase radiopharmaceutical development services to multinational pharma companies to develop novel radiopharmaceuticals into clinical use. By 2022, to support this growth, the company services became a new entity – Quantum Pharma. Quantum Pharma now has operations in Syndey and Melbourne, Australia - with plans to commence operations in Singapore in - late 2024/early 2025.
Vision
Our aim is to be known for:
- Our commitment to patient outcomes
- Our work in the area of Radiopharmaceuticals
- Our support of research and clinical translation
- Providing quality products and services to our clients and ultimately patients
- Valuing our staff
Company Principles
- Respect
- Loyalty
- Trust
- Adaptability
- Approachability
Our Team
Andrew Er - Director
FCA (Aust), FCA (S’pore), B.COM
Andrew Er is a Chartered Accountant with 20 years of working experience with a large proportion being in healthcare and financial businesses. He has led both investment in and management of healthcare businesses. In the accounting and finance domain he has previously worked for ANZ Banking Group, Ernst & Young and Mazars. He was a founding partner and director of boutique corporate finance house, Stirling Coleman Limited which specialised in taking companies for IPO. In the healthcare domain, Andrew was a lead in business development at the Parkway Group (now known as IHH). He was responsible for setting up the Casemix system (hospital classification and costing system) which was implemented throughout the Group. On the business development side, he helped set up the Gleneagles Clinical Research Centre and the Day Surgery Centre. He has also served as the General Manager at Asiamedic Limited, as a Director at Gleneagles Dialysis Centre and Health Kind International Ltd. Besides being a director of Quantum Pharma, Andrew also serves as a Director of FCC Partners, a boutique corporate finance group specializing in cross border transactions. He is also the Asia Regional Councilor for Chartered Accountants Australia and New Zealand a peak professional body.